Circulating tumor DNA in NK/T and peripheral T cell lymphoma

Yu-Jia Huo; Wei-Li Zhao

doi:10.1053/j.seminhematol.2023.07.003

Circulating tumor DNA in NK/T and peripheral T cell lymphoma

Semin Hematol. 2023 Jul;60(3):173-177. doi: 10.1053/j.seminhematol.2023.07.003. Epub 2023 Jul 26.

Authors

Yu-Jia Huo¹, Wei-Li Zhao²

Affiliations

¹ Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China. Electronic address: zhao.weili@yahoo.com.

PMID: 37563073
DOI: 10.1053/j.seminhematol.2023.07.003

Abstract

Natural killer (NK)/T-cell lymphomas (NK/TCL) and peripheral T-cell lymphomas (PTCL) are aggressive hematological malignancies. With the development of next-generation sequencing, circulating tumor DNA (ctDNA) can be detected by several techniques with clinical implications. So far, the effect of ctDNA in pretreatment prognosis prediction, longitudinal monitoring of treatment response and surveillance of long-term remission or relapse in NK/TCL and PTCL has been reported in several researches.

Keywords: NK/T cell lymphoma; Peripheral T-cell lymphoma; Prognosis; Surveillance; Treatment response; ctDNA.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Circulating Tumor DNA* / genetics
Humans
Lymphoma, T-Cell, Peripheral* / drug therapy
Lymphoma, T-Cell, Peripheral* / genetics
Lymphoma, T-Cell, Peripheral* / pathology
Neoplasm Recurrence, Local / drug therapy
Prognosis

Substances

Circulating Tumor DNA